skip to Main Content

Recorded Webinar with Dr. Colleen Delaney: Clinical Applications of Expanded Cord Blood Progenitor Cells

Share the Science

Watch the recorded webinar to hear Dr. Colleen Delaney, chief medical officer and scientific founder at Nohla Therapeutics, discuss methods for expanding cord blood stem and progenitor cells and the clinical application of these cells for cord blood transplant and chemotherapy-induced neutropenia.

 Webinar Summary

Cord blood is an effective and widely used source of stem cells for patients undergoing hematopoietic stem cell transplant for hematologic malignancies. While cord blood offers some distinct advantages over conventional stem cell sources, delayed engraftment due to the low cell dose available in each unit continues to be a challenge in the transplant setting. This webinar covers development and clinical translation of methodologies for the ex vivo expansion of cord blood stem and progenitor cells.

Dr. Delaney discusses the clinical use of expanded cord blood progenitors, which has been shown to be safe in the settings of hematopoietic transplant and dose-intensive chemotherapy. In the cord blood transplant setting, use of these expanded cells has been shown to reduce time to neutrophil and platelet recovery as well as being associated with less severe acute GVHD. In the setting of chemotherapy-induced neutropenia, expanded cells have been shown to decrease the rate of documented infections.

You will learn:

  • Methods for expansion of cord blood stem and progenitor cells
  • Clinical applications of expanded cord blood progenitor cells for cord blood transplant
  • Clinical applications of expanded cord blood progenitor cells for chemotherapy-induced neutropenia
  • Potential future applications of cord blood stem cells

Colleen Delaney, M.D., MSc, discusses methods for expansion and clinical applications of cord blood progenitor cells.

Speaker Bio

 

Dr. Colleen Delaney is a scientific founder and the chief medical officer of Nohla Therapeutics, Inc., a cellular therapy company focused on developing off-the-shelf, universal donor therapies that require no HLA matching. Dr. Delaney’s research interests focus on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications. Her group has developed a novel and clinically feasible method for the ex vivo expansion of cord-blood-derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a novel pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplant. She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off-the-shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.

Dr. Delaney holds a bachelor’s degree in molecular biology and biochemistry from Wesleyan University, an MSc in social research and social policy from Oxford University, and an M.D. from Harvard Medical School. Dr. Delaney did her residency in general pediatrics at the University of California, San Francisco and a fellowship in pediatric hematology/oncology at Fred Hutchinson Cancer Research Center/Seattle Children’s Hospital and Regional Medical Center.

columbus

 

Mediware and Save the Cord Foundation are proud to bring you this exclusive speaker series to discuss the topics you and your peers are most interested in. Join us as we feature your colleagues to discuss their latest research, opinions on industry news, and so much more. We look forward to having you on board for this exciting series!